Can this Alzheimer's trial design more cleanly test the amyloid hypothesis?

Can this Alzheimer's trial design more cleanly test the amyloid hypothesis?

STAT Plus: AC Immune bets that its Alzheimer’s trial design could provide a cleaner test of the amyloid hypothesis

By DAMIAN GARDE AND REBECCA ROBBINS AND ADAM FEUERSTEIN

NATIONAL INSTITUTE ON AGING, NIH

To study an experimental Alzheimer's drug, AC Immune recruited patients with a rare genetic mutation that almost guarantees they will develop the disease.

READ MORE